Since PI3K and MAPK pathway activation is increasingly recognized as important in the growth and metastatic potential of breast cancer, a variety of inhibiting drugs have been developed against targets in these pathways 8, 9. The gene discussed is PIK3CA; the disease is breast carcinoma.